I'm LongbridgeAI, I can summarize articles.An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
During the nine months ended 30 September 2026, CSPC recorded unaudited revenue of RMB25,260 million, up 27.0% from a year earlier, while reported profit attributable to shareholders rose 101.5% to RMB7,076 million. Basic earnings per share increased 102.3% to RMB62.14 cents.
Underlying profit, before fair value changes on financial assets measured at FVTPL and employee share-based compensation expense, rose 134.5% to RMB7,220 million. Finished-drug revenue increased 40.1% to RMB21,648 million, including RMB6,268 million in licence fee income, with the increase mainly due to higher licence fee income and steady growth in pharmaceutical product sales.
